CRISPR Gene Editing Cures Sickle Cell Disease in 98% of Trial Patients
๐ Quick Summary
A global Phase 3 clinical trial of CRISPR gene editing therapy has shown a 98% cure rate for sickle cell disease, with 210 out of 214 patients remaining symptom-free and transfusion-free after two years.